Polaryx Therapeutics Inc (PLYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Operating Expenses | 7,821 | 4,352 |
| Operating Income | -7,821 | -4,352 |
| Other Income | -1,164 | -26,004 |
| Pre-tax Income | -8,985 | -30,356 |
| Net Income Continuous | -8,985 | -30,356 |
| Net Income | $-8,985 | $-30,356 |
| EPS Basic Total Ops | -0.20 | -0.89 |
| EPS Basic Continuous Ops | -0.20 | -0.89 |
| EPS Diluted Total Ops | -0.20 | -0.89 |
| EPS Diluted Continuous Ops | -0.20 | -0.89 |
| EBITDA(a) | $-7,821 | $-4,352 |